Anti-BAFFR CART
Cell therapy
Anti-BAFFR CART is one of 40 small molecule programs targeting Neuromyelitis Optica. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Neuromyelitis Optica
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Imuran
LLegacy Health System
Approved
Novantrone
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
ENSPRYNG
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Approved
Mesnex
BBaxter Healthcare Corporation
Approved
Brukinsa
BBeOne Medicines
Approved
Ultomiris
AstraZenecaPhase 3
Medrol
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-BAFFR CART. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]